VRTX Q3 2019 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$125B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$950M+21.1% YoY

Gross Profit

$818M86.1% margin

Operating Income

$99M10.5% margin

Net Income

$58M6.1% margin

EPS (Diluted)

$0.22

QoQ Revenue Growth

+0.9%

Cash Flow

Operating Cash Flow

$335M

Free Cash Flow

$310M

Stock-Based Comp.

$85M

Balance Sheet

Total Assets

$7.5B

Total Liabilities

$2.3B

Stockholders' Equity

$5.3B

Cash & Equivalents

$3.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$950M	$785M	+21.1%
Gross Profit	$818M	$673M	+21.5%
Operating Income	$99M	$206M	-51.7%
Net Income	$58M	$129M	-55.3%

Revenue Segments

SYMDEKO/SYMKEVI

$404M43%

ORKAMBI

$297M31%

KALYDECO

$249M26%

Geographic Segments

UNITED STATES

$710M63%

Non-US

$240M21%

Europe

$185M16%